EN DE
Watch Cardiff Lexington Corp for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Cardiff Lexington Corp (CDIX) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of Cardiff Lexington Corp stock $0.00, price $0.01, that is 65.4% below the price, quality 23 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US14146R4039

CL Cardiff Lexington Corp logo Thin data Nov 14, 2026

Cardiff Lexington Corp

CDIX · US

Far too expensive (fair value 65% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Mixed Growth (revenue 5y +27.3 %/yr in USD) 
Revenue last quarter 23% below a year ago. 
Dilution deducted on Nov 15: $0.0054 → $0.0045 
Fair value $0.0045 · Strongly overvalued 
Quality 23/100 
Falling price (downtrend) 
Loss-making · -92.1% net margin (TTM) 
Trails peers (2/9) 
Narrow moat 12/100
Thin data 
⚠ Dilution
Watch Cardiff Lexington Corp for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2,003 $0.0050 Fair Value $0.0045 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range $0.0050 – $2,003 · fair‑value band $0.0043 – $0.0046 · the $0.0130 price screens above the $0.0045 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Cardiff Lexington in your weekly email

Every Wednesday you see whether Cardiff Lexington is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cardiff Lexington Corporation, through its subsidiaries, provides orthopedics, spine care, and pain management services in the United States. The company operates through two segments, Healthcare and Real Estate.

Show moreShow less

The company provides diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. It also engages in real estate business.

The company also offers orthopedic and pain procedure services, including hip and knee replacement, shoulder reconstruction, fracture care, and hand surgery, as well as spinal surgery.

It serves personal injury attorneys, insurance carriers, physical therapy providers, and chiropractic care providers. The company was formerly known as Cardiff International, Inc. and changed its name to Cardiff Lexington Corporation in January 2018.

Cardiff Lexington Corporation is based in Lexington, Kentucky.

Stock analysis

Cardiff Lexington Corp (CDIX) currently trades at $0.0130, while our model-based Fair Value estimate is $0.0045, 65% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 83/100, which puts the data coverage at low.

Scenario range: $0.0043 (bear) to $0.0046 (bull), the price of $0.0130 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cardiff Lexington Corp reported revenue of $11.5M in FY2025 versus $10.0M in FY2021, a compound +3.6%/yr. Reported net income was −$6.5M in FY2025.

Key figures

Market cap $198K Micro · EPS (TTM) $−1.00 · Net margin −92.1% · Return on equity −202% · Return on assets (EBIT) 14.4% (5-year average) · Operating margin −25.2% · Revenue (TTM) $10.2M · Revenue growth (YoY) −22.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 100% below its 52-week high and 160% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −65%, CDIX screens richer than that median.

Fair Value models

Bear $0.0043 Fair Value $0.0045 Bull $0.0046
Price $0.0130 · Downside -65.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Gordon GGM $0.0200 $0.0400 $0.0500 68
DDM Multi-Stage $0.0200 $0.0400 $0.0400 67
All 2 models by family
Dividend Discount
Gordon GGM $0.0200 $0.0400 $0.0500 68
DDM Multi-Stage $0.0200 $0.0400 $0.0400 67

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 23/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 68
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 4
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 18, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+39.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.3%
Start year 2020 (pandemic). Over 10 years: +23.6% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+108.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−34.3% (2019) → −2.3% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CDIX screens overvalued: fair value 65% below the price. Compare with HCA Healthcare, Inc →

Compare Cardiff Lexington Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 250 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −65.4% · Bottom 25%
Profitability
Return on assets −22.5% · Bottom 25%
Net margin (12 months) −92.1% · Bottom 25%
Operating margin (12 months) −25.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −22.6% · Bottom 25%
Balance sheet
Debt / equity 0.03× · Lowest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/S (12 months) 0.02× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $20.95 $45.53 +117% vs CDIX
DaVita Inc DVA $161.79 $218.90 +35% vs CDIX
Aier Eye Hospital Group 300015 ¥9.02 ¥10.88 +21% vs CDIX
HCA Healthcare, Inc HCA $476.35 $547.34 +15% vs CDIX
Tenet Healthcare Corporation THC $271.34 $279.20 +3% vs CDIX
The Ensign Group ENSG $182.98 $140.09 −23% vs CDIX
Encompass Health Corporation EHC $134.93 $94.81 −30% vs CDIX
Fresenius SE FRE €51.78 €34.77 −33% vs CDIX
Dr. Sulaiman Al Habib Medical Services Group 4013 207.90 SAR 109.45 SAR −47% vs CDIX
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,738 ₹2,908 −67% vs CDIX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cardiff Lexington Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cardiff Lexington Corp Fair Value". https://www.fairvalue-calculator.com/stock/CDIX

Frequently asked questions

Is Cardiff Lexington Corp (CDIX) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of $0.0045 versus a price of $0.0130, about 65% lower (overvalued).
What is the fair value of CDIX?
Our model-based fair value for Cardiff Lexington Corp is $0.0045 (as of Nov 14, 2026), built from audited fundamentals. The current price: $0.0130.
What is the quality score of CDIX?
Cardiff Lexington Corp has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cardiff Lexington Corp (CDIX)?
We do not set a price target; the yardstick is the fair value of $0.0045 (as of Nov 14, 2026) from 2 valuation models. Cautious scenario $0.0043, optimistic scenario $0.0046. It is a calculation from audited fundamentals, not an analyst target.
What is the Cardiff Lexington Corp stock forecast for 2026?
Our models put fair value at $0.0045, about 65% lower versus a price of $0.0130 (overvalued). Cautious scenario $0.0043, optimistic scenario $0.0046. The calculation is refreshed regularly with new filings.
What is the revenue of Cardiff Lexington Corp (CDIX)?
Cardiff Lexington Corp reported trailing-twelve-month revenue of about $10.2M (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of Cardiff Lexington Corp (CDIX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cardiff Lexington Corp it is $0.0045 per share (as of Nov 14, 2026), against a price of $0.0130. It is the blended result of 2 valuation models in 1 family (Dividend Discount).
Is Cardiff Lexington Corp stock overvalued or undervalued in 2026?
As of Nov 14, 2026, CDIX trades above its calculated fair value: price $0.0130, fair value $0.0045, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CDIX?
No. The price is what the market pays today ($0.0130); the fair value is what the company's own numbers justify ($0.0045). For Cardiff Lexington Corp the two are $0.0085 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cardiff Lexington Corp worth?
The market values Cardiff Lexington Corp at about $198K (market capitalisation, as of Nov 14, 2026). Per share that is $0.0130; our models calculate a fair value of $0.0045 per share.
What do the bullish and bearish scenarios say about CDIX?
Our models span a range for Cardiff Lexington Corp: cautious scenario $0.0043, base $0.0045, optimistic $0.0046 per share (as of Nov 14, 2026, price $0.0130). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cardiff Lexington Corp (CDIX)?
Balance-sheet figures for Cardiff Lexington Corp (as of Nov 14, 2026): return on equity −201.8%, debt of 0.03 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is CDIX from its 52-week high?
Cardiff Lexington Corp trades at $0.0130, about 100% below its 52-week high of $5.62 and 160% above the low of $0.0050 (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0045 is for.
Which stocks are comparable to Cardiff Lexington Corp?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cardiff Lexington Corp stock attractive at the current price?
The data as of Nov 14, 2026: price $0.0130, calculated fair value $0.0045 (−65%), Quality Score 23/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CDIX calculated?
We run Cardiff Lexington Corp through 2 models from 1 family: Dividend Discount. Every model gets the same audited fundamentals; the fair value of $0.0045 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Cardiff Lexington Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cardiff Lexington Corp (CDIX)?
The closing price on Nov 18, 2026 was $0.0130. Our model-based fair value is $0.0045, about 65% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cardiff Lexington Corp right now?
The price sits above even our optimistic bull case ($0.0046). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band ($0.0043 to $0.0046), unusually little disagreement for a valuation.

Key figures of Cardiff Lexington Corp

How large is the market capitalisation of Cardiff Lexington Corp (CDIX)?
The market capitalisation of Cardiff Lexington Corp is $198K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Cardiff Lexington Corp (CDIX)?
Earnings per share at Cardiff Lexington Corp are $−1.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cardiff Lexington Corp (CDIX)?
The net margin of Cardiff Lexington Corp is −92.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cardiff Lexington Corp (CDIX)?
The return on equity (ROE) of Cardiff Lexington Corp is −202% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cardiff Lexington Corp (CDIX)?
On an EBIT basis the return on assets of Cardiff Lexington Corp is 14.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cardiff Lexington Corp (CDIX)?
The operating margin of Cardiff Lexington Corp is −25.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cardiff Lexington Corp (CDIX)?
Revenue at Cardiff Lexington Corp is down 22.6% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cardiff Lexington Corp (CDIX)?
Earnings per share at Cardiff Lexington Corp are growing 19.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cardiff Lexington Corp (CDIX) generate?
The free cash flow of Cardiff Lexington Corp is −$2.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cardiff Lexington Corp (CDIX) carry?
The net debt of Cardiff Lexington Corp is $18.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cardiff Lexington Corp in the live analysis

One click puts Cardiff Lexington Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.